Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects between the ages of 18 and 65 years.~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight \>50 kg (110 lbs.)~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies).~* Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).~* A positive urine drug screen for drugs of abuse or recreational drugs.~* Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results.~* History of abuse of alcohol or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.~* Current smokers and those who have smoked any substance within the last 12 months.~* Treatment with an investigational drug within 1 month preceding the first dose of study medication.~* Have participated in any clinical study with exposure to 14\^C in the last 12 months.~* Any radiation exposure, including that which is projected to result from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures. No occupationally exposed worker, as defined in the Ionising Radiation Regulation 1999, shall participate in the study.~* Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days prior to the first dose of study medication.~* Use of herbal supplements within 28 days prior to the first dose of study medication.~* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.~* Participants who have previously participated in a clinical trial for ertugliflozin.~* Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ertugliflozin (Type: EXPERIMENTAL): Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14\^C-labeled ertugliflozin containing approximately 400 nCi 14\^C. The 14\^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14\^C-labeled ertugliflozin containing approximately 400 nCi 14\^C. Both the unlabeled and 14\^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete